IGF1R and cancer: Elevated KLHDC8A expression was associated with sensitivity as measured by AUC with an Aurora B/C kinase inhibitor, a JMJD3 inhibitor, a pan-cancer inhibitor (BRD-4132) with unknown molecular targets, and an insulin-like growth factor 1 receptor (IGF1R) inhibitor (Figure 8A).